Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

New feature: Automatically detect candlestick patterns on any chart

Tango Therapeutics Sub, Inc

Contributing Author

Recent Articles by Tango Therapeutics Sub, Inc

May-04	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TNGX +8.25% TNGX +6.56% GlobeNewswire
Apr-15	Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat TNGX +5.28% GlobeNewswire
Mar-06	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TNGX GlobeNewswire
Mar-05	Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights TNGX +36.28% GlobeNewswire
Feb-18	Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences TNGX GlobeNewswire
Feb-03	Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 TNGX +5.11% GlobeNewswire
Jan-08	Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor TNGX -6.23% GlobeNewswire
Jan-05	Tango Therapeutics Appoints Sung Lee to Board of Directors TNGX GlobeNewswire
Dec-17	Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference TNGX GlobeNewswire
Nov-26	Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference TNGX GlobeNewswire
Nov-12	Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference TNGX -8.47% GlobeNewswire
Nov-04	Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights TNGX GlobeNewswire
Oct-29	Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 TNGX GlobeNewswire
Oct-23	Tango Therapeutics Announces $225 Million Financing TNGX -13.05% GlobeNewswire
Oct-23	Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers TNGX -13.05% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)